25 XP   0   0   10

Hebei Changshan Biochem Pharma
Buy, Hold or Sell?

Let's analyse Hebei Changshan Biochem Pharma together

PenkeI guess you are interested in Hebei Changshan Biochem Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hebei Changshan Biochem Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hebei Changshan Biochem Pharma

I send you an email if I find something interesting about Hebei Changshan Biochem Pharma.

Quick analysis of Hebei Changshan Biochem Pharma (30 sec.)










What can you expect buying and holding a share of Hebei Changshan Biochem Pharma? (30 sec.)

How much money do you get?

How much money do you get?
¥0.02
When do you have the money?
1 year
How often do you get paid?
97.5%

What is your share worth?

Current worth
¥1.89
Expected worth in 1 year
¥0.52
How sure are you?
82.5%

+ What do you gain per year?

Total Gains per Share
¥-1.25
Return On Investment
-12.1%

For what price can you sell your share?

Current Price per Share
¥10.40
Expected price per share
¥6.6649 - ¥14.23
How sure are you?
50%

1. Valuation of Hebei Changshan Biochem Pharma (5 min.)




Live pricePrice per Share (EOD)

¥10.40

Intrinsic Value Per Share

¥-1.55 - ¥-1.72

Total Value Per Share

¥0.34 - ¥0.17

2. Growth of Hebei Changshan Biochem Pharma (5 min.)




Is Hebei Changshan Biochem Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$239.9m$425.3m-$111.8m-35.7%

How much money is Hebei Changshan Biochem Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$45.1m-$262.2k-$44.8m-99.4%
Net Profit Margin-114.7%-0.4%--

How much money comes from the company's main activities?

3. Financial Health of Hebei Changshan Biochem Pharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#218 / 998

Most Revenue
#146 / 998

Most Profit
#883 / 998

Most Efficient
#548 / 998

What can you expect buying and holding a share of Hebei Changshan Biochem Pharma? (5 min.)

Welcome investor! Hebei Changshan Biochem Pharma's management wants to use your money to grow the business. In return you get a share of Hebei Changshan Biochem Pharma.

What can you expect buying and holding a share of Hebei Changshan Biochem Pharma?

First you should know what it really means to hold a share of Hebei Changshan Biochem Pharma. And how you can make/lose money.

Speculation

The Price per Share of Hebei Changshan Biochem Pharma is ¥10.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hebei Changshan Biochem Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hebei Changshan Biochem Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥1.89. Based on the TTM, the Book Value Change Per Share is ¥-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hebei Changshan Biochem Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.01-0.1%-0.05-0.5%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share-0.01-0.1%-0.05-0.5%0.000.0%-0.01-0.1%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.04-0.4%0.000.0%0.000.0%0.010.0%
Usd Price Per Share1.58-1.48-0.79-0.98-1.54-
Price to Earnings Ratio-42.63--16.72-201.82-55.92-77.84-
Price-to-Total Gains Ratio-316.99--106.82-69.58-29.17-146.11-
Price to Book Ratio6.05-4.76-1.73-2.54-5.58-
Price-to-Total Gains Ratio-316.99--106.82-69.58-29.17-146.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.43624
Number of shares696
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.040.00
Gains per Quarter (696 shares)-30.13-1.86
Gains per Year (696 shares)-120.50-7.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
112-132-1319-17-17
223-264-25219-33-24
335-397-37328-50-31
447-529-49437-67-38
559-661-61546-84-45
670-793-73656-100-52
782-926-85765-117-59
894-1058-97874-134-66
9105-1190-109984-150-73
10117-1322-122093-167-80

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%7.05.00.058.3%15.05.00.075.0%34.06.00.085.0%45.06.00.088.2%
Book Value Change Per Share0.04.00.00.0%5.07.00.041.7%12.08.00.060.0%30.010.00.075.0%41.010.00.080.4%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%39.00.01.097.5%50.00.01.098.0%
Total Gains per Share0.04.00.00.0%7.05.00.058.3%14.06.00.070.0%33.07.00.082.5%44.07.00.086.3%

Fundamentals of Hebei Changshan Biochem Pharma

About Hebei Changshan Biochem Pharma

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. It offers crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadri heparin calcium API, nandroparin calcium injection, and dalteparin sodium API and injection. The company was founded in 2000 and is based in Shijiazhuang, China.

Fundamental data was last updated by Penke on 2024-05-11 12:04:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Hebei Changshan Biochem Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hebei Changshan Biochem Pharma earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Net Profit Margin of -21.0% means that ¥-0.21 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hebei Changshan Biochem Pharma:

  • The MRQ is -21.0%. The company is making a huge loss. -2
  • The TTM is -114.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-21.0%TTM-114.7%+93.7%
TTM-114.7%YOY-0.4%-114.2%
TTM-114.7%5Y-17.3%-97.4%
5Y-17.3%10Y-1.5%-15.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.0%-171.8%+150.8%
TTM-114.7%-211.9%+97.2%
YOY-0.4%-263.3%+262.9%
5Y-17.3%-414.0%+396.7%
10Y-1.5%-552.3%+550.8%
1.1.2. Return on Assets

Shows how efficient Hebei Changshan Biochem Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • -1.3% Return on Assets means that Hebei Changshan Biochem Pharma generated ¥-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hebei Changshan Biochem Pharma:

  • The MRQ is -1.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.3%TTM-6.7%+5.4%
TTM-6.7%YOY0.0%-6.7%
TTM-6.7%5Y-0.6%-6.1%
5Y-0.6%10Y0.5%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.3%-11.9%+10.6%
TTM-6.7%-11.5%+4.8%
YOY0.0%-10.9%+10.9%
5Y-0.6%-13.1%+12.5%
10Y0.5%-14.4%+14.9%
1.1.3. Return on Equity

Shows how efficient Hebei Changshan Biochem Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • -3.5% Return on Equity means Hebei Changshan Biochem Pharma generated ¥-0.04 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hebei Changshan Biochem Pharma:

  • The MRQ is -3.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-16.2%+12.7%
TTM-16.2%YOY-0.1%-16.1%
TTM-16.2%5Y-2.1%-14.2%
5Y-2.1%10Y0.1%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-15.3%+11.8%
TTM-16.2%-14.6%-1.6%
YOY-0.1%-13.6%+13.5%
5Y-2.1%-17.7%+15.6%
10Y0.1%-19.2%+19.3%

1.2. Operating Efficiency of Hebei Changshan Biochem Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hebei Changshan Biochem Pharma is operating .

  • Measures how much profit Hebei Changshan Biochem Pharma makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-11.8%+11.8%
TTM-11.8%YOY3.7%-15.5%
TTM-11.8%5Y6.6%-18.4%
5Y6.6%10Y5.0%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--336.0%+336.0%
TTM-11.8%-224.0%+212.2%
YOY3.7%-280.1%+283.8%
5Y6.6%-412.2%+418.8%
10Y5.0%-521.7%+526.7%
1.2.2. Operating Ratio

Measures how efficient Hebei Changshan Biochem Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.00 means that the operating costs are ¥2.00 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 2.003. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.345. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.003TTM2.345-0.342
TTM2.345YOY1.540+0.805
TTM2.3455Y1.501+0.844
5Y1.50110Y0.989+0.512
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0033.005-1.002
TTM2.3453.247-0.902
YOY1.5403.619-2.079
5Y1.5015.262-3.761
10Y0.9896.874-5.885

1.3. Liquidity of Hebei Changshan Biochem Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.19 means the company has ¥1.19 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 1.191. The company is just able to pay all its short-term debts.
  • The TTM is 1.550. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.191TTM1.550-0.359
TTM1.550YOY1.987-0.437
TTM1.5505Y1.987-0.437
5Y1.98710Y1.242+0.745
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1913.805-2.614
TTM1.5504.158-2.608
YOY1.9875.252-3.265
5Y1.9876.087-4.100
10Y1.2426.434-5.192
1.3.2. Quick Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Quick Ratio of 0.13 means the company can pay off ¥0.13 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.128. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.135. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.128TTM0.135-0.007
TTM0.135YOY0.222-0.087
TTM0.1355Y0.236-0.101
5Y0.23610Y0.261-0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1283.202-3.074
TTM0.1353.816-3.681
YOY0.2225.183-4.961
5Y0.2365.929-5.693
10Y0.2616.351-6.090

1.4. Solvency of Hebei Changshan Biochem Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hebei Changshan Biochem Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hebei Changshan Biochem Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63 means that Hebei Changshan Biochem Pharma assets are financed with 62.8% credit (debt) and the remaining percentage (100% - 62.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 0.628. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.564. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.628TTM0.564+0.063
TTM0.564YOY0.478+0.086
TTM0.5645Y0.427+0.138
5Y0.42710Y0.367+0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6280.344+0.284
TTM0.5640.342+0.222
YOY0.4780.279+0.199
5Y0.4270.366+0.061
10Y0.3670.380-0.013
1.4.2. Debt to Equity Ratio

Measures if Hebei Changshan Biochem Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 167.6% means that company has ¥1.68 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hebei Changshan Biochem Pharma:

  • The MRQ is 1.676. The company is just able to pay all its debts with equity.
  • The TTM is 1.325. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.676TTM1.325+0.351
TTM1.325YOY0.916+0.409
TTM1.3255Y0.796+0.529
5Y0.79610Y0.629+0.167
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6760.398+1.278
TTM1.3250.415+0.910
YOY0.9160.353+0.563
5Y0.7960.446+0.350
10Y0.6290.470+0.159

2. Market Valuation of Hebei Changshan Biochem Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hebei Changshan Biochem Pharma generates.

  • Above 15 is considered overpriced but always compare Hebei Changshan Biochem Pharma to the Biotechnology industry mean.
  • A PE ratio of -42.63 means the investor is paying ¥-42.63 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is -38.751. Based on the earnings, the company is expensive. -2
  • The MRQ is -42.626. Based on the earnings, the company is expensive. -2
  • The TTM is -16.719. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-38.751MRQ-42.626+3.875
MRQ-42.626TTM-16.719-25.907
TTM-16.719YOY201.824-218.543
TTM-16.7195Y55.918-72.637
5Y55.91810Y77.839-21.921
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-38.751-2.313-36.438
MRQ-42.626-2.535-40.091
TTM-16.719-2.723-13.996
YOY201.824-3.958+205.782
5Y55.918-6.316+62.234
10Y77.839-6.544+84.383
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is 36.345. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 39.980. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is -86.528. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD36.345MRQ39.980-3.635
MRQ39.980TTM-86.528+126.507
TTM-86.528YOY23.255-109.782
TTM-86.5285Y-2.686-83.841
5Y-2.68610Y9.887-12.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD36.345-3.099+39.444
MRQ39.980-3.270+43.250
TTM-86.528-3.523-83.005
YOY23.255-5.220+28.475
5Y-2.686-8.080+5.394
10Y9.887-8.637+18.524
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hebei Changshan Biochem Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.05 means the investor is paying ¥6.05 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hebei Changshan Biochem Pharma:

  • The EOD is 5.500. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.050. Based on the equity, the company is overpriced. -1
  • The TTM is 4.757. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.500MRQ6.050-0.550
MRQ6.050TTM4.757+1.294
TTM4.757YOY1.726+3.031
TTM4.7575Y2.544+2.213
5Y2.54410Y5.578-3.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5002.009+3.491
MRQ6.0502.029+4.021
TTM4.7572.065+2.692
YOY1.7262.688-0.962
5Y2.5443.688-1.144
10Y5.5784.095+1.483
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hebei Changshan Biochem Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.067-0.344+410%-0.012-82%-0.043-35%0.012-677%
Book Value Per Share--1.8912.444-23%3.294-43%2.993-37%2.585-27%
Current Ratio--1.1911.550-23%1.987-40%1.987-40%1.242-4%
Debt To Asset Ratio--0.6280.564+11%0.478+31%0.427+47%0.367+71%
Debt To Equity Ratio--1.6761.325+26%0.916+83%0.796+111%0.629+166%
Dividend Per Share--0.0310.030+3%0.034-8%0.024+30%0.025+24%
Eps---0.067-0.354+427%-0.002-97%-0.034-49%0.005-1334%
Free Cash Flow Per Share--0.0720.016+355%-0.086+220%-0.070+197%-0.041+157%
Free Cash Flow To Equity Per Share--0.0720.040+77%-0.025+135%-0.007+110%0.053+35%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.720--------
Intrinsic Value_10Y_min---1.547--------
Intrinsic Value_1Y_max---0.305--------
Intrinsic Value_1Y_min---0.300--------
Intrinsic Value_3Y_max---0.816--------
Intrinsic Value_3Y_min---0.781--------
Intrinsic Value_5Y_max---1.205--------
Intrinsic Value_5Y_min---1.127--------
Market Cap9558234316.800-10%10514057748.4809913933118.010+6%5317624118.625+98%6642456771.929+58%10289252632.532+2%
Net Profit Margin---0.210-1.147+447%-0.004-98%-0.173-18%-0.015-93%
Operating Margin----0.1180%0.037-100%0.066-100%0.050-100%
Operating Ratio--2.0032.345-15%1.540+30%1.501+33%0.989+103%
Pb Ratio5.500-10%6.0504.757+27%1.726+250%2.544+138%5.578+8%
Pe Ratio-38.751+9%-42.626-16.719-61%201.824-121%55.918-176%77.839-155%
Price Per Share10.400-10%11.44010.708+7%5.688+101%7.126+61%11.135+3%
Price To Free Cash Flow Ratio36.345-10%39.980-86.528+316%23.255+72%-2.686+107%9.887+304%
Price To Total Gains Ratio-288.171+9%-316.988-106.818-66%69.576-556%29.168-1187%146.113-317%
Quick Ratio--0.1280.135-5%0.222-42%0.236-46%0.261-51%
Return On Assets---0.013-0.067+409%0.000-98%-0.006-56%0.005-388%
Return On Equity---0.035-0.162+360%-0.001-98%-0.021-42%0.001-3910%
Total Gains Per Share---0.036-0.313+768%0.022-264%-0.019-47%0.037-198%
Usd Book Value--239980451.577313430979.598-23%425312551.867-44%386024109.213-38%331717631.024-28%
Usd Book Value Change Per Share---0.009-0.047+410%-0.002-82%-0.006-35%0.002-677%
Usd Book Value Per Share--0.2610.337-23%0.455-43%0.413-37%0.357-27%
Usd Dividend Per Share--0.0040.004+3%0.005-8%0.003+30%0.003+24%
Usd Eps---0.009-0.049+427%0.000-97%-0.005-49%0.001-1334%
Usd Free Cash Flow--9079519.1901925321.284+372%-11070599.395+222%-9012891.481+199%-3716421.492+141%
Usd Free Cash Flow Per Share--0.0100.002+355%-0.012+220%-0.010+197%-0.006+157%
Usd Free Cash Flow To Equity Per Share--0.0100.006+77%-0.003+135%-0.001+110%0.007+35%
Usd Market Cap1319992159.150-10%1451991375.0651369114163.597+6%734363890.782+98%917323280.203+58%1420945788.553+2%
Usd Price Per Share1.436-10%1.5801.479+7%0.785+101%0.984+61%1.538+3%
Usd Profit---8515950.026-45104065.289+430%-262267.767-97%-4345433.375-49%715729.971-1290%
Usd Revenue--40645425.08841527848.059-2%78163739.769-48%75855380.019-46%59345919.989-32%
Usd Total Gains Per Share---0.005-0.043+768%0.003-264%-0.003-47%0.005-198%
 EOD+4 -4MRQTTM+22 -12YOY+9 -265Y+11 -2410Y+11 -24

3.2. Fundamental Score

Let's check the fundamental score of Hebei Changshan Biochem Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-38.751
Price to Book Ratio (EOD)Between0-15.500
Net Profit Margin (MRQ)Greater than0-0.210
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.128
Current Ratio (MRQ)Greater than11.191
Debt to Asset Ratio (MRQ)Less than10.628
Debt to Equity Ratio (MRQ)Less than11.676
Return on Equity (MRQ)Greater than0.15-0.035
Return on Assets (MRQ)Greater than0.05-0.013
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Hebei Changshan Biochem Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.650
Ma 20Greater thanMa 5011.379
Ma 50Greater thanMa 10011.343
Ma 100Greater thanMa 20011.392
OpenGreater thanClose10.630
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,670,165
Total Liabilities2,932,436
Total Stockholder Equity1,750,036
 As reported
Total Liabilities 2,932,436
Total Stockholder Equity+ 1,750,036
Total Assets = 4,670,165

Assets

Total Assets4,670,165
Total Current Assets2,308,260
Long-term Assets2,361,905
Total Current Assets
Cash And Cash Equivalents 321,986
Net Receivables 248,026
Inventory 1,531,629
Other Current Assets 54,451
Total Current Assets  (as reported)2,308,260
Total Current Assets  (calculated)2,156,092
+/- 152,169
Long-term Assets
Property Plant Equipment 1,620,455
Intangible Assets 682,748
Long-term Assets Other 25,750
Long-term Assets  (as reported)2,361,905
Long-term Assets  (calculated)2,328,952
+/- 32,953

Liabilities & Shareholders' Equity

Total Current Liabilities1,938,685
Long-term Liabilities993,750
Total Stockholder Equity1,750,036
Total Current Liabilities
Short Long Term Debt 664,559
Accounts payable 554,152
Other Current Liabilities 20,758
Total Current Liabilities  (as reported)1,938,685
Total Current Liabilities  (calculated)1,239,469
+/- 699,217
Long-term Liabilities
Long term Debt 780,066
Capital Lease Obligations Min Short Term Debt1,507
Long-term Liabilities  (as reported)993,750
Long-term Liabilities  (calculated)781,573
+/- 212,177
Total Stockholder Equity
Retained Earnings 222,688
Total Stockholder Equity (as reported)1,750,036
Total Stockholder Equity (calculated)222,688
+/- 1,527,347
Other
Capital Stock919,061
Common Stock Shares Outstanding 919,061
Net Debt 1,122,639
Net Invested Capital 3,194,661
Net Working Capital 369,575
Property Plant and Equipment Gross 1,620,455



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302010-12-312009-12-312008-12-31
> Total Assets 
196,593
266,349
430,639
574,314
1,195,950
1,186,221
1,195,392
1,271,380
1,377,583
1,418,450
1,490,536
1,547,386
1,581,143
1,645,301
1,733,914
1,964,684
1,962,690
2,044,758
2,054,858
2,179,793
2,183,218
2,328,271
2,429,597
2,563,359
3,101,654
3,131,972
3,204,858
3,163,043
3,380,075
3,530,047
3,653,116
3,830,946
3,672,438
3,844,837
3,880,762
3,870,831
4,035,876
3,942,592
4,076,215
4,393,089
4,619,090
4,572,557
4,606,218
4,583,618
5,120,131
5,189,849
5,597,062
5,820,186
5,764,438
6,035,803
5,988,653
5,893,347
5,429,369
4,596,454
4,670,165
4,670,1654,596,4545,429,3695,893,3475,988,6536,035,8035,764,4385,820,1865,597,0625,189,8495,120,1314,583,6184,606,2184,572,5574,619,0904,393,0894,076,2153,942,5924,035,8763,870,8313,880,7623,844,8373,672,4383,830,9463,653,1163,530,0473,380,0753,163,0433,204,8583,131,9723,101,6542,563,3592,429,5972,328,2712,183,2182,179,7932,054,8582,044,7581,962,6901,964,6841,733,9141,645,3011,581,1431,547,3861,490,5361,418,4501,377,5831,271,3801,195,3921,186,2211,195,950574,314430,639266,349196,593
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,641,512
2,400,716
2,603,558
2,565,136
2,538,218
2,663,593
2,534,218
2,650,878
2,910,912
3,118,362
2,999,366
3,016,539
2,936,822
3,416,955
3,408,485
3,664,315
3,869,412
3,719,474
3,897,553
3,768,014
3,637,253
3,134,553
2,275,859
2,308,260
2,308,2602,275,8593,134,5533,637,2533,768,0143,897,5533,719,4743,869,4123,664,3153,408,4853,416,9552,936,8223,016,5392,999,3663,118,3622,910,9122,650,8782,534,2182,663,5932,538,2182,565,1362,603,5582,400,7162,641,5120000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
968,264
701,774
1,020,673
780,004
641,462
739,744
563,310
379,414
479,170
586,196
481,016
439,945
278,612
570,418
543,214
604,037
678,516
455,634
797,797
584,794
554,582
311,079
230,923
321,986
321,986230,923311,079554,582584,794797,797455,634678,516604,037543,214570,418278,612439,945481,016586,196479,170379,414563,310739,744641,462780,0041,020,673701,774968,2640000000000000000000000000000000
       Net Receivables 
33,221
27,177
74,214
98,109
72,068
78,768
90,688
90,131
95,403
128,119
158,354
147,780
120,269
147,279
173,931
146,974
127,499
159,331
152,052
149,952
140,871
165,519
129,064
135,571
127,790
173,022
168,530
189,983
246,512
412,031
376,637
344,419
322,292
360,726
341,415
321,465
288,863
373,309
357,334
401,812
409,661
470,966
485,159
404,660
327,117
356,332
316,709
326,746
387,787
496,020
477,426
338,059
198,650
206,135
248,026
248,026206,135198,650338,059477,426496,020387,787326,746316,709356,332327,117404,660485,159470,966409,661401,812357,334373,309288,863321,465341,415360,726322,292344,419376,637412,031246,512189,983168,530173,022127,790135,571129,064165,519140,871149,952152,052159,331127,499146,974173,931147,279120,269147,780158,354128,11995,40390,13190,68878,76872,06898,10974,21427,17733,221
       Other Current Assets 
3,121
29,586
6,622
9,332
34,935
53,572
102,003
127,603
202,230
143,636
259,447
289,091
390,789
357,377
431,883
425,604
457,759
253,104
352,560
376,940
341,985
219,893
234,589
191,227
195,343
152,458
204,702
228,275
257,429
86,633
203,614
248,920
305,058
138,618
9,182
10,764
11,500
189,195
285,612
264,843
243,808
159,641
189,916
172,450
225,158
223,680
306,413
285,455
265,033
172,242
248,385
218,097
82,953
62,833
54,451
54,45162,83382,953218,097248,385172,242265,033285,455306,413223,680225,158172,450189,916159,641243,808264,843285,612189,19511,50010,7649,182138,618305,058248,920203,61486,633257,429228,275204,702152,458195,343191,227234,589219,893341,985376,940352,560253,104457,759425,604431,883357,377390,789289,091259,447143,636202,230127,603102,00353,57234,9359,3326,62229,5863,121
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,315,626
1,332,613
1,372,283
1,408,374
1,425,337
1,482,176
1,500,728
1,573,191
1,589,680
1,646,796
1,703,176
1,781,363
1,932,747
1,950,774
2,044,964
2,138,250
2,220,639
2,256,094
2,294,816
2,320,595
2,361,905
2,361,9052,320,5952,294,8162,256,0942,220,6392,138,2502,044,9641,950,7741,932,7471,781,3631,703,1761,646,7961,589,6801,573,1911,500,7281,482,1761,425,3371,408,3741,372,2831,332,6131,315,6260000000000000000000000000000000000
       Property Plant Equipment 
46,753
45,669
107,111
56,022
72,382
138,381
91,288
210,664
164,404
277,627
244,211
342,665
310,126
419,252
400,825
434,384
473,580
499,329
507,619
530,201
552,137
565,724
578,650
616,957
622,854
662,447
770,505
725,369
749,264
769,515
773,386
795,906
810,679
849,476
891,932
911,563
903,060
935,317
927,431
957,803
966,594
1,064,193
1,060,263
1,079,787
1,121,579
1,192,553
1,275,851
1,317,485
1,432,093
1,483,330
1,507,591
1,546,279
1,573,580
1,591,402
1,620,455
1,620,4551,591,4021,573,5801,546,2791,507,5911,483,3301,432,0931,317,4851,275,8511,192,5531,121,5791,079,7871,060,2631,064,193966,594957,803927,431935,317903,060911,563891,932849,476810,679795,906773,386769,515749,264725,369770,505662,447622,854616,957578,650565,724552,137530,201507,619499,329473,580434,384400,825419,252310,126342,665244,211277,627164,404210,66491,288138,38172,38256,022107,11145,66946,753
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,356
4,356
4,356
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
3,556
1,778
1,778
1,778
1,778
0
0
001,7781,7781,7781,7783,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5563,5564,3564,3564,35600000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,958
14,385
8,196
10,342
8,142
9,453
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000009,4538,14210,3428,19614,38523,9580000000000000000000000000000000
       Intangible Assets 
28,269
27,589
57,366
56,715
56,389
56,063
55,737
12,163
76,502
11,274
77,888
10,385
124,839
56,536
120,418
118,374
116,330
113,175
111,188
109,272
107,288
105,383
165,422
163,201
160,945
158,849
156,597
154,345
152,676
194,839
192,246
184,608
186,190
183,513
275,130
124,374
278,869
281,267
282,848
372,235
376,032
401,776
410,383
417,425
472,097
493,127
521,273
528,136
543,037
547,954
570,121
654,435
661,244
680,241
682,748
682,748680,241661,244654,435570,121547,954543,037528,136521,273493,127472,097417,425410,383401,776376,032372,235282,848281,267278,869124,374275,130183,513186,190184,608192,246194,839152,676154,345156,597158,849160,945163,201165,422105,383107,288109,272111,188113,175116,330118,374120,41856,536124,83910,38577,88811,27476,50212,16355,73756,06356,38956,71557,36627,58928,269
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
127,598
121,507
164,954
167,853
193,621
103,835
1,085,835
65,611
79,772
113,822
79,045
68,096
111,033
86,561
50,918
86,469
125,309
30,001
25,296
23,409
25,750
25,75023,40925,29630,001125,30986,46950,91886,561111,03368,09679,045113,82279,77265,6111,085,835103,835193,621167,853164,954121,507127,5980000000000000000000000000000000000
> Total Liabilities 
103,163
107,154
211,253
312,985
230,504
198,775
188,789
211,476
296,818
292,773
340,637
380,356
345,148
359,778
425,604
622,789
600,836
617,869
601,785
704,781
681,831
757,072
743,276
861,119
783,704
842,591
870,817
801,110
968,131
1,094,656
1,170,850
1,393,949
1,190,776
1,321,812
1,299,820
1,226,290
1,345,901
1,220,318
1,302,030
1,531,389
1,802,944
1,719,329
1,685,340
1,579,548
2,070,893
2,117,729
2,497,756
2,713,991
2,659,586
2,981,780
2,934,750
3,005,985
2,775,774
2,796,762
2,932,436
2,932,4362,796,7622,775,7743,005,9852,934,7502,981,7802,659,5862,713,9912,497,7562,117,7292,070,8931,579,5481,685,3401,719,3291,802,9441,531,3891,302,0301,220,3181,345,9011,226,2901,299,8201,321,8121,190,7761,393,9491,170,8501,094,656968,131801,110870,817842,591783,704861,119743,276757,072681,831704,781601,785617,869600,836622,789425,604359,778345,148380,356340,637292,773296,818211,476188,789198,775230,504312,985211,253107,154103,163
   > Total Current Liabilities 
103,163
106,501
197,173
247,735
165,151
182,482
172,738
194,856
280,246
273,033
318,051
358,391
321,227
334,135
392,533
588,907
567,605
589,819
573,321
662,329
641,967
717,731
705,242
824,130
747,323
736,373
565,636
540,670
709,054
787,881
865,455
1,089,935
887,309
1,087,225
1,066,534
993,359
1,112,139
1,188,125
1,271,162
1,261,844
1,495,086
1,412,071
1,379,551
1,403,780
1,895,066
1,734,044
1,966,300
2,151,738
1,957,967
1,787,946
1,820,229
1,716,342
1,839,375
1,920,921
1,938,685
1,938,6851,920,9211,839,3751,716,3421,820,2291,787,9461,957,9672,151,7381,966,3001,734,0441,895,0661,403,7801,379,5511,412,0711,495,0861,261,8441,271,1621,188,1251,112,139993,3591,066,5341,087,225887,3091,089,935865,455787,881709,054540,670565,636736,373747,323824,130705,242717,731641,967662,329573,321589,819567,605588,907392,533334,135321,227358,391318,051273,033280,246194,856172,738182,482165,151247,735197,173106,501103,163
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
697,000
726,648
840,137
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000840,137726,648697,0000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
697,000
726,648
840,137
617,557
820,961
950,800
1,238,291
1,011,859
944,052
843,624
1,427,309
1,231,905
1,470,928
1,760,598
1,421,374
971,316
1,034,923
1,105,926
849,824
927,045
664,559
664,559927,045849,8241,105,9261,034,923971,3161,421,3741,760,5981,470,9281,231,9051,427,309843,624944,0521,011,8591,238,291950,800820,961617,557840,137726,648697,0000000000000000000000000000000000000
       Accounts payable 
11,017
1,581
11,171
40,594
4,210
3,887
4,635
3,843
4,677
4,261
10,837
18,703
18,570
17,616
15,989
22,244
22,357
34,899
38,312
26,858
34,548
70,813
55,998
123,851
123,160
60,074
40,944
41,541
32,991
38,913
42,100
47,668
39,037
56,739
125,500
69,833
45,880
80,668
61,428
46,176
36,571
82,354
114,903
61,625
70,092
106,490
101,285
72,422
208,768
249,809
157,441
152,367
98,863
263,377
554,152
554,152263,37798,863152,367157,441249,809208,76872,422101,285106,49070,09261,625114,90382,35436,57146,17661,42880,66845,88069,833125,50056,73939,03747,66842,10038,91332,99141,54140,94460,074123,160123,85155,99870,81334,54826,85838,31234,89922,35722,24415,98917,61618,57018,70310,8374,2614,6773,8434,6353,8874,21040,59411,1711,58111,017
       Other Current Liabilities 
16,346
20,720
11,721
10,847
20,941
20,095
13,103
40,013
30,069
44,272
42,714
43,488
42,657
52,719
55,544
50,630
48,248
54,921
55,009
57,124
65,606
76,918
59,244
170,280
131,163
103,851
127,073
115,326
108,007
186,864
198,355
119,012
143,934
147,687
219,428
134,078
200,290
176,043
213,347
138,229
191,879
212,391
286,645
295,261
231,421
184,793
182,970
139,755
158,293
122,560
161,834
113,919
38,840
25,685
20,758
20,75825,68538,840113,919161,834122,560158,293139,755182,970184,793231,421295,261286,645212,391191,879138,229213,347176,043200,290134,078219,428147,687143,934119,012198,355186,864108,007115,326127,073103,851131,163170,28059,24476,91865,60657,12455,00954,92148,24850,63055,54452,71942,65743,48842,71444,27230,06940,01313,10320,09520,94110,84711,72120,72016,346
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233,286
232,931
233,761
32,193
30,868
269,545
307,858
307,258
305,789
175,767
175,827
383,685
531,455
562,253
701,618
1,193,834
1,114,522
1,289,644
936,399
875,840
993,750
993,750875,840936,3991,289,6441,114,5221,193,834701,618562,253531,455383,685175,827175,767305,789307,258307,858269,54530,86832,193233,761232,931233,2860000000000000000000000000000000000
       Other Liabilities 
0
653
14,080
15,250
15,353
16,293
16,051
16,620
16,572
16,058
19,057
18,582
20,648
22,425
29,954
30,866
30,317
25,210
25,713
39,805
37,516
37,062
35,867
34,939
34,442
104,330
103,386
105,737
104,480
105,270
103,979
104,014
103,467
34,587
33,286
32,931
33,761
32,193
30,868
29,545
27,858
25,846
24,390
28,592
28,653
51,215
48,847
66,065
67,091
64,991
64,786
63,058
0
0
0
00063,05864,78664,99167,09166,06548,84751,21528,65328,59224,39025,84627,85829,54530,86832,19333,76132,93133,28634,587103,467104,014103,979105,270104,480105,737103,386104,33034,44234,93935,86737,06237,51639,80525,71325,21030,31730,86629,95422,42520,64818,58219,05716,05816,57216,62016,05116,29315,35315,25014,0806530
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
73,828
76,066
80,657
94,196
97,494
102,928
108,093
111,935
122,608
127,985
150,175
166,030
173,844
195,636
219,837
252,965
261,505
277,647
0
310,445
330,037
0
0
0
000330,037310,4450277,647261,505252,965219,837195,636173,844166,030150,175127,985122,608111,935108,093102,92897,49494,19680,65776,06673,8280000000000000000000000000000000
> Total Stockholder Equity
93,429
159,195
219,385
261,329
965,446
987,446
1,006,602
1,033,331
1,054,359
1,099,631
1,124,314
1,140,591
1,179,550
1,229,321
1,253,457
1,286,911
1,306,912
1,369,777
1,394,703
1,415,302
1,442,492
1,513,541
1,542,814
1,558,106
2,173,529
2,228,835
2,271,829
2,298,383
2,347,649
2,369,451
2,414,831
2,425,268
2,470,582
2,512,818
2,571,620
2,636,041
2,682,130
2,714,925
2,767,225
2,855,190
2,809,961
2,847,580
2,916,032
2,999,469
3,045,624
3,068,784
3,096,771
3,106,057
3,107,567
3,058,046
3,061,907
2,896,698
2,664,226
1,811,657
1,750,036
1,750,0361,811,6572,664,2262,896,6983,061,9073,058,0463,107,5673,106,0573,096,7713,068,7843,045,6242,999,4692,916,0322,847,5802,809,9612,855,1902,767,2252,714,9252,682,1302,636,0412,571,6202,512,8182,470,5822,425,2682,414,8312,369,4512,347,6492,298,3832,271,8292,228,8352,173,5291,558,1061,542,8141,513,5411,442,4921,415,3021,394,7031,369,7771,306,9121,286,9111,253,4571,229,3211,179,5501,140,5911,124,3141,099,6311,054,3591,033,3311,006,602987,446965,446261,329219,385159,19593,429
   Common Stock
49,292
80,850
80,850
80,850
107,850
107,850
107,850
107,850
188,419
188,419
188,419
188,419
188,419
188,419
188,419
188,419
188,419
188,419
188,419
471,047
471,047
471,047
471,047
847,884
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
934,967
0
934,967
934,967
0
0
0
000934,967934,9670934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967934,967847,884471,047471,047471,047471,047188,419188,419188,419188,419188,419188,419188,419188,419188,419188,419188,419107,850107,850107,850107,85080,85080,85080,85049,292
   Retained Earnings 
8,044
15,697
69,869
111,813
118,669
133,589
152,745
179,474
170,117
200,908
222,378
235,444
250,689
285,248
344,746
376,519
394,839
456,024
480,079
499,807
526,127
596,305
625,201
640,116
671,677
746,827
789,821
816,375
865,641
929,722
975,101
1,017,115
1,072,002
1,051,009
985,674
1,052,296
1,097,074
1,326,228
1,375,009
1,444,728
1,518,695
1,566,916
1,635,481
1,723,876
1,774,002
1,800,490
1,830,141
1,841,355
1,843,883
1,794,108
1,798,649
1,633,634
1,215,542
284,353
222,688
222,688284,3531,215,5421,633,6341,798,6491,794,1081,843,8831,841,3551,830,1411,800,4901,774,0021,723,8761,635,4811,566,9161,518,6951,444,7281,375,0091,326,2281,097,0741,052,296985,6741,051,0091,072,0021,017,115975,101929,722865,641816,375789,821746,827671,677640,116625,201596,305526,127499,807480,079456,024394,839376,519344,746285,248250,689235,444222,378200,908170,117179,474152,745133,589118,669111,81369,86915,6978,044
   Capital Surplus 0000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-60,421
-69,994
0
2,146
-54
1,257
-73,112
-69,593
-51,346
-65,566
-61,133
-61,247
-66,205
-70,176
-73,503
-75,168
-77,096
-78,114
-77,859
-78,540
-78,734
0
0
0
000-78,734-78,540-77,859-78,114-77,096-75,168-73,503-70,176-66,205-61,247-61,133-65,566-51,346-69,593-73,1121,257-542,1460-69,994-60,4210000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,410,440
Cost of Revenue-1,093,062
Gross Profit317,377317,377
 
Operating Income (+$)
Gross Profit317,377
Operating Expense-1,884,595
Operating Income-474,155-1,567,217
 
Operating Expense (+$)
Research Development158,824
Selling General Administrative554,074
Selling And Marketing Expenses0
Operating Expense1,884,595712,898
 
Net Interest Income (+$)
Interest Income1,841
Interest Expense-96,414
Other Finance Cost-3,126
Net Interest Income-97,699
 
Pretax Income (+$)
Operating Income-474,155
Net Interest Income-97,699
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,231,695-474,155
EBIT - interestExpense = -96,414
-1,240,211
-1,143,797
Interest Expense96,414
Earnings Before Interest and Taxes (EBIT)0-1,135,281
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-1,231,695
Tax Provision-16,459
Net Income From Continuing Ops-1,248,154-1,248,154
Net Income-1,240,211
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net097,699
 

Technical Analysis of Hebei Changshan Biochem Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hebei Changshan Biochem Pharma. The general trend of Hebei Changshan Biochem Pharma is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hebei Changshan Biochem Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hebei Changshan Biochem Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.00 < 14.10 < 14.23.

The bearish price targets are: 9.18 > 7.56 > 6.6649.

Tweet this
Hebei Changshan Biochem Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hebei Changshan Biochem Pharma. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hebei Changshan Biochem Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hebei Changshan Biochem Pharma. The current macd is -0.09782256.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hebei Changshan Biochem Pharma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hebei Changshan Biochem Pharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hebei Changshan Biochem Pharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hebei Changshan Biochem Pharma Daily Moving Average Convergence/Divergence (MACD) ChartHebei Changshan Biochem Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hebei Changshan Biochem Pharma. The current adx is 15.93.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hebei Changshan Biochem Pharma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Hebei Changshan Biochem Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hebei Changshan Biochem Pharma. The current sar is 12.40.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hebei Changshan Biochem Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hebei Changshan Biochem Pharma. The current rsi is 39.65. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Hebei Changshan Biochem Pharma Daily Relative Strength Index (RSI) ChartHebei Changshan Biochem Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hebei Changshan Biochem Pharma. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hebei Changshan Biochem Pharma price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hebei Changshan Biochem Pharma Daily Stochastic Oscillator ChartHebei Changshan Biochem Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hebei Changshan Biochem Pharma. The current cci is -123.80760896.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Hebei Changshan Biochem Pharma Daily Commodity Channel Index (CCI) ChartHebei Changshan Biochem Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hebei Changshan Biochem Pharma. The current cmo is -34.2267783.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hebei Changshan Biochem Pharma Daily Chande Momentum Oscillator (CMO) ChartHebei Changshan Biochem Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hebei Changshan Biochem Pharma. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Hebei Changshan Biochem Pharma Daily Williams %R ChartHebei Changshan Biochem Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hebei Changshan Biochem Pharma.

Hebei Changshan Biochem Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hebei Changshan Biochem Pharma. The current atr is 0.53679619.

Hebei Changshan Biochem Pharma Daily Average True Range (ATR) ChartHebei Changshan Biochem Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hebei Changshan Biochem Pharma. The current obv is 2,692,965,596.

Hebei Changshan Biochem Pharma Daily On-Balance Volume (OBV) ChartHebei Changshan Biochem Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hebei Changshan Biochem Pharma. The current mfi is 34.13.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hebei Changshan Biochem Pharma Daily Money Flow Index (MFI) ChartHebei Changshan Biochem Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hebei Changshan Biochem Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Hebei Changshan Biochem Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hebei Changshan Biochem Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.650
Ma 20Greater thanMa 5011.379
Ma 50Greater thanMa 10011.343
Ma 100Greater thanMa 20011.392
OpenGreater thanClose10.630
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hebei Changshan Biochem Pharma with someone you think should read this too:
  • Are you bullish or bearish on Hebei Changshan Biochem Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hebei Changshan Biochem Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hebei Changshan Biochem Pharma

I send you an email if I find something interesting about Hebei Changshan Biochem Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about Hebei Changshan Biochem Pharma.

Receive notifications about Hebei Changshan Biochem Pharma in your mailbox!